SCHEMBL5625932

SCHEMBL5625932

CC(C)(C)OC(=O)N1Cc2cc(NC(=O)c3ccccc3NCc3cccc4nccnc34)ccc2C(C)(C)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 6/20 0.40
NAMPT P43490 1/20 0.37
KDR P35968 5/20 0.36
FLT1 P17948 3/20 0.36
KIT P10721 3/20 0.36
ABL1 P00519 2/20 0.36
EGFR P00533 2/20 0.36
CSF1R P07333 2/20 0.36
PDGFRB P09619 2/20 0.36
FLT4 P35916 2/20 0.36
PTGES O14684 1/20 0.36
NR1H2 P55055 1/20 0.36
MAPT P10636 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ACHE P22303 1/20 0.35
BRAF P15056 2/20 0.34
CIT O14578 1/20 0.34
MAP3K7 O43318 1/20 0.34
RIPK2 O43353 1/20 0.34
STK10 O94804 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5628140 0.84 KIT (0.37) RXFP1NAMPTKDRFLT1KIT
SCHEMBL14348672 0.83 KIT (0.40) RXFP1NAMPTKDRFLT1KIT
SCHEMBL5626921 0.82 KIT (0.44) KITBRAF
SCHEMBL5626252 0.82 KIT (0.54) RXFP1NAMPTKDRKITNR1H2
SCHEMBL5627073 0.82 RXFP1 (0.41) RXFP1NAMPTKDRFLT1KIT
SCHEMBL5668151 0.81 RXFP1 (0.37) RXFP1NAMPTKDRFLT1KIT
SCHEMBL5626135 0.81 KIT (0.42) RXFP1KDRFLT1KITABL1
SCHEMBL446984 0.79 KDR (0.42) KDRFLT1KITABL1EGFR
SCHEMBL3818526 0.77 POLB (0.50) KDRNR1H2MAPT
SCHEMBL4975909 0.77 VCP (0.43) NAMPTKDRFLT1KITABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7307088-B2 Substituted anthranilic amide derivatives and methods of use AMGEN INC. (US) 2007-12-11 US disclosed
US-7307088-B2 Substituted anthranilic amide derivatives and methods of use AMGEN INC. (US) 2007-12-11 US disclosed
US-7307088-B2 Substituted anthranilic amide derivatives and methods of use AMGEN INC. (US) 2007-12-11 US disclosed
EP-1519921-A2 SUBSTITUTED ANTHRANILIC AMIDE DERIVATIVES AND METHODS OF USE Amgen Inc. (US) 2005-04-06 EP disclosed
US-20040087568-A1 Substituted anthranilic amide derivatives and methods of use AMGEN INC. 2004-05-06 US disclosed
WO-2004005279-A2 SUBSTITUTED ANTHRANILIC AMIDE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087568-A1 Substituted anthranilic amide derivatives and methods of use AADAC, ASPH, EGLN3 RXFP1 1275/4885NAMPT 32/4885KDR 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.